The Alzheimer's Disease Anti-inflammatory Prevention Trial - Follow-up Study (ADAPT-FS) is continued observation of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), a randomized, parallel, placebo-controlled, multicenter trial designed to test the efficacy of a non-selective, non-steroidal anti-inflammatory drug and a selective COX-2 inhibitor for the prevention of Alzheimer's disease and attenuation of age-related cognitive decline.
The treatment regimens, which were administered in parallel, are: naproxen sodium (220 mg b.i.d.), celecoxib (200 mg b.i.d.) and matching placebos. ADAPT enrolled 2,528 participants who screened negative for dementia, were age 70 or older at enrollment and had a history of Alzheimer-like dementia in a first-degree relative. Participants have been unmasked to their original treatment assignment.